Clinical trials: Secukinumab
Rotator Cuff Tendinopathy
Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
The purpose of the present study was to assess the efficacy of secukinumab 300 mg s.c. (subcutaneous) compared to placebo, each in combination with standard of care, in improving signs, symptoms and physical function in…
- Trial name
- NCT05722522
- Testing
- Secukinumab
- Where
- 15 sites in United States, Argentina and 5 more
- Volunteers
- 33 people
- Sponsor
- Novartis Pharmaceuticals
Ankylosing Spondyloarthritis
Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis
The purpose of this trial is to demonstrate the clinical efficacy at week 16; and to demonstrate safety and tolerability of secukinumab compared to placebo in patients with ankylosing spondylitis at week 16 and long term safety…
- Trial name
- NCT02896127
- Testing
- Secukinumab
- Where
- 44 sites in China, Czechia and 2 more
- Volunteers
- 458 people
- Sponsor
- Novartis Pharmaceuticals
Psoriatic Arthritis
Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment
The purpose of this study is to compare the safety and efficacy of secukinumab and ustekinumab in patients with active psoriatic arthritis who showed failure to previous TNFα-inhibitor treatment
- Trial name
- AgAIN (NCT04632927)
- Testing
- Secukinumab, Ustekinumab
- Where
- 28 sites in Germany
- Volunteers
- 119 people
- Sponsor
- Novartis Pharmaceuticals
Moderate to Severe Nail Psoriasis
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
This purpose of this study was to demonstrate the efficacy of secukinumab versus placebo on nail psoriasis and to assess long-term efficacy, safety and tolerability of secukinumab.
- Trial name
- TRANSFIGURE (NCT01807520)
- Testing
- Secukinumab
- Where
- 40 sites in United States, Australia and 7 more
- Volunteers
- 198 people
- Sponsor
- Novartis Pharmaceuticals
Moderate to Severe Plaque-type Psoriasis
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
The purpose of this study is to demonstrate efficacy of secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.
- Trial name
- FEATURE (NCT01555125)
- Testing
- secukinumab 150 mg, secukinumab 300 mg
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 177 people
- Sponsor
- Novartis Pharmaceuticals
Thyroid Eye Disease, Graves Orbitopathy
A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)
Thyroid eye disease (TED) is a rare autoimmune, inflammatory disorder of the orbit and represents the most common extra-thyroidal manifestation of Graves' disease (GD).
- Trial name
- ORBIT (NCT04737330)
- Testing
- Secukinumab
- Where
- 5 sites in Germany
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Anklyosing Spondylitis
16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
This study assessed the efficacy and safety of secukinumab in patients with active ankylosing spondylitis who were tolerant to or had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor
- Trial name
- MEASURE2 (NCT01649375)
- Testing
- Secukinumab (75 mg), Secukinumab (150 mg)
- Where
- 53 sites in United States, Austria and 11 more
- Volunteers
- 219 people
- Sponsor
- Novartis Pharmaceuticals
Necrobiosis Lipoidica Diabeticorum
Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)
This study investigates the efficacy of secukinumab in necrobiosis lipoidica diabeticorum (NLD).
- Trial name
- NCT03791060
- Testing
- Secukinumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Beth Israel Deaconess Medical Center
Plaque Psoriasis
Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
The purpose of this study was to determine if secukinumab is effective and safe in the treatment of plaque type psoriasis
- Trial name
- NCT03066609
- Testing
- Secukinumab 150 mg s.c., Secukinumab 300 mg s.c.
- Where
- 32 sites in China, Hungary and 4 more
- Volunteers
- 543 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.
This is a randomized, controlled, multicenter, open-label study with blinded assessment of the efficacy of subcutaneous secukinumab compared to Fumaderm®, in 200 adults with moderate to severe plaque type psoriasis who are…
- Trial name
- PRIME (NCT02474082)
- Testing
- Secukinumab, Fumaric acid
- Where
- 32 sites in Germany
- Volunteers
- 202 people
- Sponsor
- Novartis Pharmaceuticals
Psoriatic Arthritis
Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo
To demonstrate that the efficacy of secukinumab 300 mg at Week 16 was superior to placebo in adult patients with active PsA based on the proportion of patients achieving an American College of Rheumatology 20 (ACR20) response.
- Trial name
- NCT02798211
- Testing
- Secukinumab 300 mg, Secukinumab 150 mg
- Where
- 58 sites in United States, Puerto Rico
- Volunteers
- 258 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
This study will assess at Week 16 the efficacy and safety of AIN457 at different doses in patients with active RA despite stable MTX therapy.
- Trial name
- NCT00928512
- Testing
- Secukinmab
- Where
- 58 sites in United States, Belgium and 9 more
- Volunteers
- 237 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis
The primary purpose of this study is to assess efficacy, safety and tolerability of a 2 mL pre-filled auto-injector (AI) of 300 mg secukinumab in patients with moderate to severe plaque psoriasis
- Trial name
- MATURE (NCT03589885)
- Testing
- Secukinumab 2 mL auto-injector, Secukinumab 1 mL prefilled syringe
- Where
- 22 sites in United States, Canada and 4 more
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Psoriatic Arthritis
Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)
This study was designed to leverage the sensitivity of ultrasonography available in clinical practice setting to better describe the time course of response to secukinumab (150 mg and 300 mg) on joint synovitis and enthesitis in…
- Trial name
- PDUS (NCT02662985)
- Testing
- AIN457 (secukinumab)
- Where
- 33 sites in United States, Argentina and 15 more
- Volunteers
- 166 people
- Sponsor
- Novartis Pharmaceuticals
Non-radiographic Spondyloarthritis
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
The purpose of this study was to demonstrate the clinical efficacy, safety and tolerability of secukinumab compared to placebo in patients with nr-axSpA at Week 16 as well as Week 52 and long term efficacy and safety up to Week…
- Trial name
- PREVENT (NCT02696031)
- Testing
- Secukinumab
- Where
- 139 sites in United States, Australia and 22 more
- Volunteers
- 555 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Plaque Type Psoriasis
Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis
This study assessed efficacy of secukinumab, compared to ustekinumab, in patients that have plaque-type psoriasis
- Trial name
- NCT02074982
- Testing
- AIN457 300 mg, ustekinumab 45/90 mg
- Where
- 137 sites in United States, Australia and 22 more
- Volunteers
- 676 people
- Sponsor
- Novartis Pharmaceuticals
Ichthyosis, Autosomal Recessive Congenital Ichthyosis
The Efficacy and Safety of Secukinumab in Patients With Ichthyoses
The ichthyoses are a group of lifelong genetic disorders which share characteristics of generalized skin thickening, scaling and underlying cutaneous inflammation.
- Conditions
- Ichthyosis, Autosomal Recessive Congenital Ichthyosis, Lamellar Ichthyosis, Congenital Ichthyosiform Erythroderma
- Trial name
- NCT03041038
- Testing
- Secukinumab
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Northwestern University
Chronic Plaque Psoriasis
Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis
This study will assess the safety and efficacy of secukinumab compared to placebo and etanercept in patients that have moderate to severe, chronic, plaque-type psoriasis.
- Trial name
- FIXTURE (NCT01358578)
- Testing
- secukinumab (AIN457), etanercept
- Where
- 152 sites in United States, Argentina and 21 more
- Volunteers
- 1,306 people
- Sponsor
- Novartis Pharmaceuticals
Lupus Nephritis
Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis
This was a pivotal, randomized, double-blind, placebo-controlled trial evaluating at Week 52 the efficacy and safety of secukinumab versus placebo in patients with active lupus nephritis (ISN/RPS Class III or IV, with or without…
- Trial name
- SELUNE (NCT04181762)
- Testing
- secukinumab
- Where
- 105 sites in United States, Argentina and 32 more
- Volunteers
- 275 people
- Sponsor
- Novartis Pharmaceuticals
Psoriatic Arthritis, Axial Spondyloarthritis
Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site
The purpose of this study was to demonstrate efficacy, including effects on inflammation by magnetic resonance imaging (MRI) assessments, of secukinumab on Achilles tendon enthesitis for up to 1 year with a primary focus at Week…
- Conditions
- Psoriatic Arthritis, Axial Spondyloarthritis, Enthesitis
- Trial name
- ACHILLES (NCT02771210)
- Testing
- Secukinumab
- Where
- 55 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 204 people
- Sponsor
- Novartis Pharmaceuticals